Glaxo S.p.a.

Zambon Group S.p.a.

Simes Societa Italiana Medicinali E Sintetici S.p.a.

Isf S.p.a.

Claudio Semeraro

Giovanni Gaviraghi

Francesco Santangelo

Dino Micheli

Daniele Pieraccioli

Alan D Borthwick

Gabriele Pietro Norcini

Cesare Casagrande

Franco Pellacini

Stefania Montanari

Stefano Romagnano

Francesco Marchini

Giorgio Bertolini

Mario Fantucci

Allan D Borthwick

Mario Pinza

Giorgio Pifferi

Giancarlo Grancini

Paolo Cavalleri

Daniela Botta

Luciano Dorigotti

Cristina Fraire

Lorenzo Pradella

Napoletano Mauro

Hydroxymethyl derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene as cardiovascular agent

Thiol derivatives with metallopeptidase (ACE/NEP) inhibitory activity

Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described. The compounds of formula I are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Mercapto acyl aminoacid derivatives endowed with dual ACE-NEP inhibitory

Thiol derivatives with metallopeptidase inhibitory activity

Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and n have the meanings reported in the description are described. The compounds of formula I are endowed with a dual ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Phosphinic acid derivatives with metallopeptidase inhibitory activity

Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene and their use in therapeutic field are described. The compounds are particularly useful in the treatment of arterial hypertension, cardiac decompensation and renal failure, in the treatment of peripheral arteriopathies and in cerebrovascular insufficiency.

2-amino-1,2,3,4-tetrahydronaphthalene derivatives active on the

Compounds are described of the formula: ##STR1## and physiologically acceptable salts thereof, in which R.sub.1 -R.sub.7 are defined hereinafter. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion concentration and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

Heterocyclic compounds and their preparation and pharmaceutical

Compounds of formula ##STR1## (wherein R, R.sub.1, R.sub.2, R.sub.3, n, m and p have the meanings reported in the specification), their preparation and the compositions for pharmaceutical use containing them as active ingredient are described. The compounds of formula I have dopaminergic vasodilator activity and they may be used in pharmaceutical field.

Phenoxyethyl amine compounds active on the cardiovascular system

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;

Heterocyclic compounds and their pharmaceutical formulation

Compounds of formula ##STR1## (wherein R, R.sub.1, R.sub.2, R.sub.3, n, m, and p have the meanings reported in the specification), their preparation and the compositions for pharmaceutical use containing them as active ingredient are described. The compounds of formula I have dopaminergic vasodilator activity and they may be used in pharmaceutical field.

Compounds active on the cardiovascular system

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group:

Heterocyclic 1,4 dihydropyridine derivatives

1.4-dihydro pyridines

Pyridinedicarboxylic acid derivatives and pharmaceutical compositions

1.4-dihydropyridines

Growing community of inventors

Bresso, Italy

Claudio Semeraro